Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Oxford Immunotec Global PLC    OXFD   GB00BGFBB958

OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
11.91(c) 12.04(c) 11.89(c) 11.96(c) 12.13(c) Last
86 984 233 756 110 401 92 282 59 865 Volume
+0.42% +1.09% -1.25% +0.59% +1.42% Change
More quotes
Financials ($)
Sales 2017 103 M
EBIT 2017 -44,0 M
Net income 2017 -46,5 M
Finance 2017 40,5 M
Yield 2017 -
Sales 2018 117 M
EBIT 2018 -26,5 M
Net income 2018 -28,7 M
Finance 2018 15,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 2,56x
EV / Sales2018 2,48x
Capitalization 305 M
More Financials
Company
Oxford Immunotec Global Plc is a medical diagnostics company, which engages in the developing and commercializing of proprietary tests for under-served immune-regulated conditions.Its current product lines and development activities principally focus on four areas: infectious diseases,... 
More about the company
Surperformance© ratings of Oxford Immunotec Global PL
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD IMMUNOTEC GLOBAL PL
01/08Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Ye..
GL
01/03Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Confere..
GL
2017QIAGEN : and Oxford Immunotec Settle Patent Infringement Lawsuit
PR
2017Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
GL
2017OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
2017Oxford Immunotec Announces Update in Patent Infringement Litigation
GL
2017Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference
GL
2017Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering..
GL
2017Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Sh..
GL
2017OXFORD IMMUNOTEC GLOBAL PLC : Investor Network: Oxford Immunotec Global PLC to H..
AC
More news
Sector news : Medical Diagnostic & Testing Equipment
02/19Siemens Healthineers on track for March IPO
RE
02/08ATHENAHEALTH : Former GE CEO Jeff Immelt Named Chairman of Athenahealth -- Updat..
DJ
02/07GENERAL ELECTRIC : Former GE CEO Jeff Immelt Named Chairman of Athenahealth
DJ
02/03ROYAL PHILIPS : Investors Seek Answers on Health Fund -- WSJ
DJ
02/02ROYAL PHILIPS : Abraaj Investors Hire Auditor to Trace Money
DJ
More sector news : Medical Diagnostic & Testing Equipment
Latest Tweets
02/22Oxford Immunotec Global PLC $OXFD Receives $18.75 Consensus Price Target from.. 
02/22Favorable Press Coverage Somewhat Unlikely to Impact Oxford Immunotec Global .. 
02/22Oxford Immunotec $OXFD PT Lowered to $19 at BTIG Ahead of Q4 Earnings Report .. 
02/20Stanley Laman Group Ltd. Acquires Shares of 49,514 Oxford Immunotec Global PL.. 
02/20TREND REVERSAL UP ALERT: $OXFD OXFORD IMMUNOTEC GLOBAL PLC OR ? TradeIdeas vi.. 
More tweets
Qtime:56
News from SeekingAlpha
01/12Oxford Immunotec Global (OXFD) Presents At 36th Annual J.P. Morgan Healthcare.. 
01/08Midday Gainers / Losers 
01/08Oxford Immunotec sees Q4 top line of ~$25M, shy of consensus; shares down 15% 
2017Oxford Immunotec, Qiagen settle patent litigation 
2017Oxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q3 2017 Results .. 
Chart OXFORD IMMUNOTEC GLOBAL PL
Duration : Period :
Oxford Immunotec Global PL Technical Analysis Chart | OXFD | GB00BGFBB958 | 4-Traders
Technical analysis trends OXFORD IMMUNOTEC GLOBAL PL
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 17,8 $
Spread / Average Target 49%
EPS Revisions
Managers
NameTitle
Peter James Wrighton-Smith Chief Executive Officer & Executive Director
Richard Alvin Sandberg Chairman
Stefan C. Linn Chief Operating Officer
Richard M. Altieri Chief Financial & Accounting Officer
Richard J. Wenstrup Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD IMMUNOTEC GLOBAL PLC-14.39%305
SARTORIUS AG (PREFERENCE)36.03%9 619
SARTORIUS AG35.24%9 619
MYRIAD GENETICS, INC.-4.79%2 327
VAREX IMAGING CORP-9.78%1 379
NH SPECIAL PURPOSE ACQTN 2ND CO LTD--.--%414